Do plasma substitutes have additional properties beyond correcting volume deficits?
The best strategy for volume therapy has been the focus of debate and there are still no unique accepted guidelines. There is increasing evidence that some plasma substitutes possess additional effects on organ perfusion, microcirculation, tissue oxygenation, inflammation, endothelial activation, capillary leakage, and tissue edema that are beyond their volume replacing properties. Whether the different plasma substitutes differ with regard this additional effects was reviewed. The additional effects of plasma substitutes have mostly been studied experimentally or in animals, much less results are available in humans. The results are not uniform ranging from beneficial to even detrimental effects of a certain volume replacement strategy. Some important results from the literature are not reflected in the actual recommendations for treating volume deficits in the critically ill: although crystalloids have been shown to have considerable negative effects on microcirculation, organ perfusion, tissue oxygenation, and endothelial integrity, they are still often recommended as first choice volume replacement strategy. In several experimental studies hypertonic solutions have been shown to have various beneficial effects, they have not been, however, translated into humans. In future, the choice of the ideal volume replacement regimen should not only be focused on its volume restoring properties, but additional effects (e.g. on organ perfusion on, tissue oxygenation, inflammation, endothelial activation, capillary leakage) should also be taken into account when treating hypovolemia in the critically ill.
Boldt
Joachim
J
Department of Anesthesiology and Intensive Care Medicine, Klinikum der Stadt Ludwigshafen, Bremserstrasse 79, D-67063 Ludwigshafen, Germany. BoldtJ@gmx.net
D000818:Animals; D001810:Blood Volume; D002199:Capillary Permeability / Q000187:drug effects*; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000187:drug effects*; D006801:Humans; D020896:Hypovolemia / Q000628:therapy*; D007249:Inflammation; D008833:Microcirculation / Q000187:drug effects; D010084:Oxidation-Reduction / Q000187:drug effects; D010101:Oxygen Consumption / Q000187:drug effects*; D010477:Perfusion / Q000009:adverse effects; D010952:Plasma Substitutes / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*
D010952:Plasma Substitutes